Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Adverse effects of androgen deprivation therapy (ADT) are a consequence of the induced sex steroid deficiency. ADT increases fat mass leading to insulin resistance and diabetes, and accelerates bone loss causing increased fracture risk. Given the high prevalence of cardiovascular disease and reduced bone density in ADT-naïve men with prostate cancer, the benefits of ADT have to be carefully weighed against its side effects, especially as a diagnosis of prostate cancer does not alter the life expectancy for most men. Men commencing ADT should be counselled about and be carefully monitored for these and other ADT-induced complications, which include fatigue, sexual dysfunction, hot flushes and anaemia. ADT-associated side effects should be prevented and treated in order that ADT-induced toxicity does not outweigh its benefits. Future clinical trials are needed: first, to better define the effects of ADT on survival in men with localized prostate cancer or with biochemical prostate-specific antigen recurrence; second, to delineate ADT-associated harm, especially with respect to cardiovascular events and fractures; and third, to test the efficacy of interventions designed to minimize ADT-related adverse outcomes. Such information will be essential to better quantify the risk-benefit ratio of ADT in the individual man with prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Low testosterone levels are common and associated with insulin resistance in men with diabetes
Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2177 · Cited by 468
Self-citationLevine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383
Testosterone and type 2 diabetes
Grossmann, M., Gianatti, E. J., & Zajac, J. D. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833919cf · Cited by 108
Self-citation
Cited by
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment
Grossmann, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0118 · Cited by 350
Self-citationTajar, A., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Bartfai, G., Boonen, S., Casanueva, F. F. F., Forti, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2513 · Cited by 318
The role of androgens in metabolism, obesity, and diabetes in males and females
Navarro, G., Allard, C., Xu, W., & Mauvais‐Jarvis, F. (2015) · Obesity · doi:10.1002/oby.21033 · Cited by 289
Sex hormones and their receptors regulate liver energy homeostasis
Shen, M., & Shi, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/294278 · Cited by 239
“increases their risk of diabetes [112, 113] and not only increases”
Background
Metadata
- Authors
- Grossmann, M., & Zajac, J. D.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2011-02-08
- Volume
- 74
- Issue
- 3
- Pages
- 289-293
- ISSN
- 0300-0664 (ISSN-L)
- OpenAlex
- W2129688106
- Cited by
- 68
- References
- 5
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? https://app.cochat.ai/papers/10.1111/j.1365-2265.2010.03939.x
- The paper
- Grossmann, M., & Zajac, J. D. (2011). Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2010.03939.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.